Sarah Lofgren is part of a team of researchers conducting a trial of hydroxychloroquine. Working out of the University of Minnesota, the team is providing the drug to First Responders to assess the impact in preventing the onset of COVID-19 as well as the drug’s ability to mitigate the more severe symptoms of the disease.
Among the topics of discussion are:
The impact of anecdotal evidence of hydroxychloroquine’s
useage around the world.
Does a pandemic offer an excuse to relax drug approval protocols?
Why use First Responders in a hydroxychloroquine trial?
Can therapies like hydroxychloroquine provide enough breathing space
to get America back to work?
Members of Congress recently paraded a mix of recommended updates to benefit military service members…
The ByteDance-owned TikTok faces an uphill battle in the United States after President Joe Biden…
Promising to grow space for integrating and delivering on critical defense programs by more than…
In unsealing a 13-page indictment this week, the U.S. Department of Justice (DOJ) revealed charges…
A bill targeting the illicit fentanyl supply chain, the Fentanyl Eradication and Narcotics Deterrence (FEND)…
In order to move the state closer to federal standards and allow reporting of local…
This website uses cookies.